A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited's healthcare fund ("CEL Healthcare Fund"), and WuXi PharmaTech announced today that the Consortium ...
Tribute Pharmaceuticals Canada Inc., a specialty pharmaceutical company with a primary focus on...
Investors started shedding Achillion shares early Wednesday, less than a day after the drugmaker...
CVS Health will spend more than $10 billion to buy pharmacy services provider Omnicare and tap a...
US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par Pharma by TPG to Endo was announced on Monday. The US Pharma industry has seen 39 deals valued at US$ 77.3bn to-date, three more deals announced ...
Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and ...
Endo International will spend about $8.05 billion to acquire Par Pharmaceutical as it pushes further into the generic drug market. Endo CEO Rajiv De Silva said the deal make Endo one of the top five generics companies as measured by U.S. sales.
Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.
Eli Lilly and Company and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies.
ProPharma Group, a compliance services company, today announced its acquisition of PROSAR, a provider of pharmacovigilance and medical information services.
Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.
Juno Therapeutics, a biopharmaceutical company focused on cancer treatment, announced today that it has acquired Stage Cell Therapeutics GmbH.
Endo International has acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas.
BASF recently announced plans to sell several prominent pharmaceutical ingredients to Siegfried Holding AG for $306 million.
The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.
MorphoSys AG announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.
Alexion Pharmaceuticals will pay a huge premium to buy fellow rare disease treatment maker Synageva BioPharma in an $8.4-billion deal for a company with no products on the market.
PlasmaTech Biopharmaceuticals has acquired Abeona Therapeutics, a company engaged in the development and commercialization of therapies for patients with lysosomal storage diseases.
Juno Therapeutics and Fate Therapeutics announced a strategic collaboration to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product for potentially treating cancer patients.
Portola Pharmaceuticals today announced a collaboration with Ora, Inc. for the development of Portola's highly selective Syk inhibitor, PRT2761, in ophthalmic diseases.
Immune Pharmaceuticals and STC Biologics are entering into a strategic partnership to accelerate the development of NanomAbs, a new generation of Antibody Nanoparticle Conjugates allowing the targeted delivery of chemo-therapeutics.
Mylan N.V. today announced that it has increased its offer to acquire the issued and to be issued shares of Perrigo.
Net sales of the brand is trending on an annual rate exceeding $4 million.
After a comprehensive review, the Mylan board concluded the approach did not meet any of the key criteria that would cause Mylan to depart from the company's longstanding strategy.
Mylan made an unsolicited $28.9 billion offer to buy the Irish drugmaker last week, but Perrigo’s board of directors unanimously rejected the proposal, saying that the merger substantially undervalues the company and its future growth prospects.
The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma.
Mylan Executive Chairman Robert J. Coury commented, "We note that there has been some media speculation with regard to a potential bid for Mylan by Teva and that this rumor has been circulating for some time."
Sartorius Stedim Biotech (SSB), an international supplier for the biopharmaceutical industries, today acquired the Scottish company BioOutsource Ltd.
Medytox currently owns and operates several healthcare companies, including clinical testing laboratories, an electronic medical records provider, a laboratory information systems company and a medical billing company. CollabRx is a leading informatics company focused on the interpretation of complex molecular and genetic tests in cancer.
- Page 1